systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-127Research ArticleСТАТЬИARTICLESНовые Европейские рекомендации по ведению пациентов с артериальной гипертонией: место сартановЧазоваИ. Е.noemail@neicon.ruФГУ РКНПК Росмедтехнологий, МоскваRussian Federation2008231220225247Copyright © Чазова И.Е., 20222022Чазова И.Е.Чазова И.Е.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/127ReferencesGuidelines for the management of arterial hypertension. J Hypertension 2007; 25: 1105-87.Guidelines for the management of arterial hypertension. J Hypertension 2007; 25: 1105-87.Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998; 20 (4): 671-81.Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998; 20 (4): 671-81.Hasford J, Mimran A, Simons WR. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Human Hypertension 2002; 16 (8): 569-75.Hasford J, Mimran A, Simons WR. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Human Hypertension 2002; 16 (8): 569-75.Parving HH et al. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345 (12): 870-8.Parving HH et al. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345 (12): 870-8.Lewis EJ et al. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (12): 851-60.Lewis EJ et al. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (12): 851-60.
The authors declare that there are no conflicts of interest present.